Topic Cancer Immunotherapies
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Unexpected Success for a TKI in Activating Anticancer Innate Immunity
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT1118Published: Nov 2018Expires: 1/1/2026Sources: Oncology TimesDetails -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Unexpected Success for a TKI in Activating Anticancer Innate Immunity ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN1118Published: Nov 2018Expires: 1/1/2026Sources: Oncology TimesDetails -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Realizing the Promise of Immunotherapy in the Clinic
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0516Published: May 2016Expires: 1/1/2026Sources: Oncology TimesDetailsRequired Passing Score: 7/10 (70%)Specialties: OncologyTopics: Cancer Immunotherapies , ImmunotherapiesMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Realizing the Promise of Immunotherapy in the Clinic ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0516Published: May 2016Expires: 1/1/2026Sources: Oncology TimesDetailsRequired Passing Score: 7/10 (70%)Specialties: OncologyTopics: Cancer Immunotherapies , ImmunotherapiesMedia: